The development of new monometallic bifunctional catalysts with Lewis acid and Lewis base properties, and their application in asymmetric cyanation reactions

Chemistry - A European Journal

Volumn 7, Issue 24, 2001, Pages 5246-5251

  Gröger, Harald ^a  

^a EVONIK INDUSTRIES AG   (Germany)

Author keywords

Asymmetric catalysis; Bifunctional catalysts; Cyanohydrins; Ligand design; Nucleophilic addition

Indexed keywords

ACIDS; ALDEHYDES; CHEMICAL REACTIONS;

LEWIS ACIDS;

CATALYSTS;

ACID; ALDEHYDE DERIVATIVE; BASE; IMINE; LEWIS ACID; LEWIS BASE; METAL DERIVATIVE; PHOSPHINE DERIVATIVE; UNCLASSIFIED DRUG;

CATALYSIS; CATALYST; CHEMICAL REACTION; CHIRALITY; CYANATION; ENANTIOMER; REACTION TIME; REVIEW; STEREOCHEMISTRY; SYNTHESIS;

EID: 0035905571     PISSN: 09476539     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-3765(20011217)7:24<5246::aid-chem5246>3.0.co;2-o     Document Type: Article

References (45)

1. a) G. Helmchen, R. W. Hoffmann, J. Mulzer, E. Schaumann, Houben-Weyl, Methods of Organic Chemistry, Stereoselective Synthesis, Vol. E21, Thieme, Stuttgart/New York, 1995;
2. b) Catalytic Asymmetric Synthesis, 2nd ed. (Ed.: I. Ojima), Wiley-VCH, Weinheim, 2000;
3. c) Comprehensive Asymmetric Catalysis I-III (Eds.: E. N. Jacobsen, A. Pfaltz, H. Yamamoto), Springer, Berlin, 1999.
4. Lewis Acids in Organic Synthesis (Ed.: H. Yamamoto), Wiley-VCH, Weinheim, 2000.
5. For a review, see: E. J. Corey, C. J. Helal, Angew. Chem. 1998, 110, 2092-2118;
6. Angew. Chem. Int. Ed. 1998, 37, 1986-2012.
7. For a review, see: R. Noyori, M. Kitamura, Angew. Chem. 1991, 103, 34-55;
8. Angew. Chem. Int. Ed. Engl. 1991, 30, 34-48.
9. For reviews, see: a) M. Shibasaki, H. Sasai, T. Arai, Angew. Chem. 1997, 109, 1290-1310;
10. Angew. Chem. Int. Ed. Engl. 1997, 36, 1236-1256;
11. b) M. Shibasaki, H. Gröger in Topics in Organometallic Chemistry Vol.2: Lanthanides: Chemistry and Use in Organic Synthesis (Ed.: S. Kobayashi), Springer, Berlin, 1999, pp. 199-233.
12. a) Y. Ito, M. Sawamura, T. Hayashi, J. Am. Chem. Soc. 1986, 108, 6405-6406;
13. b) T. Hayashi, M. Sawamura, Y. Ito, Tetrahedron 1992, 48, 1999-2012.
14. For reviews on the application of bifunctional catalysts in asymmetric synthesis, see: a) H. Steinhagen, G. Helmchen, Angew. Chem. 1996, 103, 2489-2492;
15. Angew. Chem. Int. Ed. Engl. 1996, 35, 2337-2340;
16. b) G. J. Rowland, Tetrahedron 2001, 57, 1865-1882;
17. c) E. K. van der Beuken, B. L. Feringa, Tetrahedron 1998, 54, 12985-13011.
18. Y. Hamashima, D. Sawada, M. Kanai, M. Shibasaki, J. Am. Chem. Soc. 1999, 121, 2641-2642.
19. In previous work on bimetallic asymmetric catalysis it was found that aluminum complexes bearing binaphthoxide moieties have been very efficient in several asymmetric reactions, see: a) T. Arai, H. Sasai, K. Aoe, K. Okamura, T. Date, M. Shibasaki, Angew. Chem. 1996, 108, 103-105;
20. Angew. Chem. Int. Ed. Engl. 1996, 35, 104-106;
21. b) see ref. [7a];
22. c) K. Ishihara, J. Kobayashi, K. Inanaga, H. Yamamoto, Synlett 2001, 394-396.
23. Cyanohydrins are of industrial importance, since these molecules are key building blocks for a broad range of compounds, for example, β-amino alcohols and α-hydroxy acids. Furthermore, cyanohydrins are applied as intermediates in the production of pyrethroids. For reviews about the synthesis and applications of chiral cyanohydrins, see: a) M. North, Synlett 1993, 807-820;
24. b) F. Effenberger, Angew. Chem. 1994, 106, 1609-1619;
25. Angew. Chem. Int. Ed. Engl. 1994, 33, 1555-1564;
26. c) R. J. H. Gregory, Chem. Rev. 1999, 99, 3649-3682.
27. D. Sawada, M. Shibasaki, Angew. Chem. 2000, 112, 215-218;
28. Angew. Chem. Int. Ed. 2000, 39, 209-213.
29. Epothilones show potent antitumor activity, thus representing promising drug candidates; for a review on the total synthesis and biology of epothilones, see: K. C. Nicolaou, F. Roschangar, D. Vourloumis, Angew. Chem. 1998, 110, 2120-2153;
30. Angew. Chem. Int. Ed. 1998, 37, 2014-2045.
31. M. Kanai, Y. Hamashima, M. Shibasaki, Tetrahedron Lett. 2000, 41, 2405-2409.
32. a) Y. Hamashima, M. Kanai, M. Shibasaki, J. Am. Chem. Soc. 2000, 122, 7412-7413;
33. b) Y. Hamashima, M. Kanai, M. Shibasaki, Tetrahedron Lett. 2001, 42, 691-694.
34. L. Yet, Angew. Chem. 2001, 113, 900-902;
35. Angew. Chem. Int. Ed. 2001, 40, 875-877.
36. a) M. Takamura, Y. Hamashima, H. Usuda, M. Kanai, M. Shibasaki, Angew. Chem. 2000, 112, 1716-1718;
37. Angew. Chem. Int. Ed. 2000, 39, 1650-1652;
38. b) M. Takamura, Y. Hamashima, H. Usuda, M. Kanai, M. Shibasaki, Chem. Pharm. Bull. 2000, 48, 1586-1592;
39. c) H. Nogami, S. Matsunaga, M. Kanai, M. Shibasaki, Tetrahedron Lett. 2001, 42, 279-283.
40. a) M. Takamura, K. Funabashi, M. Kanai, M. Shibasaki, J. Am. Chem. Soc. 2000, 122, 6327-6328;
41. b) M. Takamura, K. Funabashi, M. Kanai, M. Shibasaki, J. Am. Chem. Soc. 2001, 123, 6801-6808.
42. Bestatin is used clinically as an anticancer agent; for selected examples of the synthesis of bestatin or its components, see: a) H. Nemoto, R. Ma, I. Suzuki, M. Shibuya, Org. Lett. 2000, 2, 4245-4247, and references therein;
43. b) S. C. Bergmeier, D. M. Stanchina, J. Org. Chem. 1999, 64, 2852-2859, and references therein;
44. c) F. Matsuda, T. Matsumoto, M. Ohsaki, Y. Ito, S. Terashima, Bull. Chem. Soc. Jpn. 1992, 65, 360-365, and references therein.
45. G. Manickam, H. Nogami, M. Kanai, H. Gröger, M. Shibasaki, Synlett 2001, 617-620.